Shin Tokunaga

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials.

Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials.

Journal: PloS one
Published: March 12, 2026

Tenapanor reduces phosphate binder pill burden among hemodialysis patients in a post hoc phase 3 analysis.

Tenapanor reduces phosphate binder pill burden among hemodialysis patients in a post hoc phase 3 analysis.

Journal: Scientific reports
Published: January 28, 2026

Estimating the impact of pill burden on health utilities in hemodialysis therapy.

Estimating the impact of pill burden on health utilities in hemodialysis therapy.

Journal: Scientific reports
Published: June 12, 2025

Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.

Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.

Journal: Endocrinology
Published: October 18, 2022

Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," [Kidney Int. Rep. 2021; https://doi.org/10.1016/j.ekir.2021.08.020].

Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," [Kidney Int. Rep. 2021; https://doi.org/10.1016/j.ekir.2021.08.020].

Journal: Kidney international reports
Published: November 26, 2021

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients.

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients.

Journal: Kidney international reports
Published: April 27, 2021

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.

Journal: PloS one
Published: April 20, 2021

Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study.

Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study.

Journal: BMJ open
Published: July 01, 2020

The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs.

The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs.

Journal: PloS one
Published: June 02, 2020

Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.

Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.

Journal: PloS one
Published: January 16, 2020

Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA®)

Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA®)

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: July 17, 2019

Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.

Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.

Journal: Bioorganic & medicinal chemistry letters
Published: March 26, 2018
Showing 1-12 of 13

Last Updated: 09/26/2026